Clinical Trials Browser

Phase 2/3 × pembrolizumab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome

NCT04534205 2026-02-12

AHEAD-MERIT

Phase 2/3 Recruiting

350 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06295731 2025-11-17

HexAgon-HN

Phase 2/3 Recruiting

410 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06082167 2025-08-17

STELLAR-305

Phase 2/3 Active not recruiting

600 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/3 Terminated

1 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Clinical Trials

FORTIFI-HN01

AHEAD-MERIT

HexAgon-HN

STELLAR-305

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)